Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target

1 Mar 2024

Abstract excerpt

BACKGROUND: The current standard treatment for Helicobacter pylori infection, which involves a combination of two broad-spectrum antibiotics, faces significant challenges due to its detrimental impact on the gut microbiota and the emergence of drug-resistant strains. This underscores the urgent requirement for the development of novel anti-H. pylori drugs. Zoliflodacin, a novel bacterial gyrase inhibitor, is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Helicobacter pylori-related gastroenterology studies
Share to Reproductive tract infections research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38627919
DOI: 10.1111/hel.13075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB targetPMID 38627919Read ↗

Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.Semantic proximity Read ↗

GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.Semantic proximity Read ↗

A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA GyraseSemantic proximity Read ↗

Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enzymological Basis for Cellular TargetingSemantic proximity Read ↗

The GyrA encoded gene: A pertinent marker for the phylogenetic revision of Helicobacter genusSemantic proximity Read ↗

Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility.Semantic proximity Read ↗

Zoliflodacin and gepotidacin cross-resistance in <i>Neisseria gonorrhoeae</i>Semantic proximity Read ↗

In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.Semantic proximity Read ↗

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.Semantic proximity Read ↗

Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695Semantic proximity Read ↗

In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.Semantic proximity Read ↗

Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.